Held by 6 specialist biotech funds
High Convergence# Signal Note: Driehaus Capital Initiates $128.6M Position in BridgeBio Driehaus' entry signals conviction in BridgeBio's pipeline depth across rare genetic diseases, particularly BBP-418 (oculopharyngeal muscular dystrophy) and BBP-631 (glycogen storage disease type III), both in clinical development with near-term readout potential.
AI analyst context — unlock full analysis
# Signal Note: EcoR1 Capital Initiates $35.3M Position in BridgeBio EcoR1's new stake signals confidence in BridgeBio's late-stage pipeline, likely driven by upcoming catalysts in rare genetic diseases where the company has multiple Phase 2/3 programs (notably in osteogenesis imperfecta and other monogenic disorders). The $35.3M entry by a growth-stage crossover fund—which typically deploys ahead of inflection points—suggests conviction in near-term clinical or commercial inflection, potentially timed to anticipated data readouts or regulatory progression in 2024-2025.
+ 4 more positions with dollar amounts and AI context
Unlock All — 7-Day Free Trial